These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9367703)

  • 41. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.
    Valk GD; Kappelle AC; Tjon-A-Tsien AM; Bravenboer B; Bakker K; Michels RP; Groenhout CM; Bertelsmann FW
    J Neurol; 1996 Mar; 243(3):257-63. PubMed ID: 8936356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The ACTH (4-9) analog ORG 2766 in panic disorder: a preliminary study.
    den Boer JA; Westenberg HG; Mastenbroek B; van Ree JM
    Psychopharmacol Bull; 1989; 25(2):204-8. PubMed ID: 2557650
    [No Abstract]   [Full Text] [Related]  

  • 43. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
    Gandara DR; Perez EA; Weibe V; De Gregorio MW
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.
    Bravenboer B; Hendrikse PH; Oey PL; van Huffelen AC; Groenhout C; Gispen WH; Erkelens DW
    Diabetologia; 1994 Apr; 37(4):408-13. PubMed ID: 8063043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 46. Cisplatin neurotoxicity.
    Mollman JE
    N Engl J Med; 1990 Jan; 322(2):126-7. PubMed ID: 2152970
    [No Abstract]   [Full Text] [Related]  

  • 47. Interventions for preventing neuropathy caused by cisplatin and related compounds.
    Albers JW; Chaudhry V; Cavaletti G; Donehower RC
    Cochrane Database Syst Rev; 2011 Feb; (2):CD005228. PubMed ID: 21328275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vibratory perception threshold in the lower extremities. Normative values.
    Urban P; Jandak Z; Lukas E; Prochazka B
    Cent Eur J Public Health; 1995 Nov; 3(4):234-7. PubMed ID: 8903528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer.
    Marin AC; Rierson B
    Ariz Med; 1979 Dec; 36(12):898-9. PubMed ID: 229809
    [No Abstract]   [Full Text] [Related]  

  • 50. Prevention of peripheral nerve damage in leprosy.
    Richardus JH
    Lepr Rev; 1990 Dec; 61(4):404. PubMed ID: 2177816
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.
    Gerritsen van der Hoop R; de Koning P; Boven E; Neijt JP; Jennekens FG; Gispen WH
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):637-42. PubMed ID: 2838292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity.
    Elderson A; Gerritsen van der Hoop R; Haanstra W; Neijt JP; Gispen WH; Jennekens FG
    J Neurol Sci; 1989 Nov; 93(2-3):167-74. PubMed ID: 2592981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats.
    Sporel-Ozakat RE; Edwards PM; Van der Hoop RG; Gispen WH
    Eur J Pharmacol; 1990 Sep; 186(2-3):181-7. PubMed ID: 1963145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
    Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
    Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer.
    Pradat PF; Finiels F; Kennel P; Naimi S; Orsini C; Delaere P; Revah F; Mallet J
    Hum Gene Ther; 2001 Mar; 12(4):367-75. PubMed ID: 11242529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 57. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats.
    Hamers FP; van der Hoop RG; Steerenburg PA; Neijt JP; Gispen WH
    Toxicol Appl Pharmacol; 1991 Dec; 111(3):514-22. PubMed ID: 1660632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog.
    Soininen H; Koskinen T; Helkala EL; Pigache R; Riekkinen PJ
    Neurology; 1985 Sep; 35(9):1348-51. PubMed ID: 2991817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ACTH analogue application to oncostatic chemotherapy. A double blind approach.
    Piazza E; Cattaneo MT; Colombo F; Libretti A
    Ric Clin Lab; 1984; 14(2):257-9. PubMed ID: 6091252
    [No Abstract]   [Full Text] [Related]  

  • 60. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
    Smyth JF; Bowman A; Perren T; Wilkinson P; Prescott RJ; Quinn KJ; Tedeschi M
    Ann Oncol; 1997 Jun; 8(6):569-73. PubMed ID: 9261526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.